Selected Publications

Hepatitis B Virus (HBV) Publications

Korba BE, Furman PA, and Otto MJ. 2006. Clevudine: A potent inhibitor of hepatitis B virus in vitro and in vivo. Expert Rev. Anti. Infect. Ther. 2006, 4(4): 549-561.

Zoulim F. Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. Journal of Antimicrobial Chemotherapy. 2005, Vol.55, 608–611.

Marcellin P, Mommeja-Marin H, Sacks SL, Lau GKK, Sereni D, Bronowicki J-P, Conway B, Trepo C, Blum MR, Yoo BC, Mondou E, Sorbel J, Snow A, Rousseau F, Lee H-S. A Phase II Dose-Escalating Trial of Clevudine in Patients with Chronic Hepatitis B. Hepatology. 2004, Vol.40, No.1.

Summers J, Mason WS. Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy. PNAS, 2004, Vol.101, No.2, 638-640.

Peek SF, Cote PJ, Jacob JR, Toshkov IA, Hornbuckle WE, Baldwin BH, Wells FV, Chu CK, Gerin JL, Tennant BC, Korba BE. Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, L-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax).Hepatology.2001, 33:1(254-266).

Zhu Y, Yamamoto T, Cullen J, Saputelli J, Aldrich CE, Miller DS, Litwin S, Furman PA, Jilbert AR, Mason, WS. Kinetics of Hepadnavirus Loss from the Liver during Inhibition of Viral DNA Synthesis. J. Virology. 2001, Vol.75, No.1. 311-322.

Hepatitis C Virus (HCV) Publications

Clark JL, Hollecker L, Mason JC, Stuyver LJ, Tharnish PM, Lostia S, McBrayer TR, Schinazi RF, Watanabe KA, Otto MJ, Furman PA, Stec WJ, Patterson SE, Pankiewicx KW. Design, synthesis, and antiviral activity of 2’-deoxy-2’-fluoro-2’-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J. Med. Chem. 2005, 48(17): 5504-5508.

Stuyver LJ, McBrayer TR, Thranish PM, Clark J, Hollecker L, Lostia S, Nachman T, Grier J, Bennett MA, Xie M-Y, Schinazi RF, Morrey JD, Julander JL, Furman PA, and Otto MJ. Inhibition of hepatitis C replicon RNA synthesis by β-D-2’-deoxy-2’-fluoro-2’-methylcytidine: A specific inhibitor of hepatitis C virus replication. Antiviral Chem. and Chemother. 2006, 17: 79-87.

Murakami E, Bao H, Ramesh M, McBrayer TR, Whitaker T, Micolochick Steuer HM, Schinazi RF, Stuyver LJ, Obikhod A, Otto MJ, Furman PA. Mechanism of activation of {beta}-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother. November 2006.

Stuyver LJ, McBrayer TR, Whitaker T, Tharnish PM, Ramesh M, Lostia S, Cartee L, Shi, Hobbs A, Schinazi RF, Watanabe KA, Otto MJ. Inhibition of the Subgenomic Heptatitis C Virus Replicon in Huh-7 cells by 2'-Deoxy-2'-Fluorocytidine. Antimicrob Agents Chemother. 2004 Feb;77(19):651-654.

Stuyver LJ, McBrayer TR, Tharnish PM, Hassan AEA, Chu CK, Pankiewicz K, Watanabe KA, Schinazi RF, Otto MJ. Dynamics of subgenomic heptatitis C virus replicon RNA levels in huh-7 cells after exposure to Nucleoside Antimetabolites. J Virol. 2003 Oct;77(19):10689-10694.

Human Immunodeficiency Virus (HIV) Publications

Herzmann C, Arasteh K. Murphy RL, Schulbin H, Kreckel P, Drauz D, Schinazi RF, Beard A, Cartee L, Otto MJ. Safety, Pharmacokinetics, and Efficacy of (+/–)-β-2’,3’-Dideoxy-5-Fluoro-3’-Thiacytidine with Efavirenz and Stavudine in Antiretroviral-Naïve Human Immunodeficiency Virus-Infected Patients. 2005. Antimicrobial Agents and Chemotherapy. Vol.49, No.7, 2828-2833.